Despite Attractive End Markets, Analyst Outlines Concerns For Repligen Stock

  • RBC Capital Markets has initiated coverage on Repligen Corporation RGEN with a Sector Perform rating and a price target of $190.
  • The analyst likes the company due to product differentiation in some of the fastest-growing areas of biopharma.
  • But RBC is hesitant towards the stock due to the 12.7x sales multiple, lack of operational earnings beats, declining gross margins, and low absolute R&D investment relative to larger companies in the space.
  • Related: Repligen Beefs Up Process Analytics Portfolio With DRS Daylight Solutions Pact.
  • Repligen is a pure play in the biopharma production sector, which has exploded over the last 2-3 years and remains the fastest-growing market in life sciences, tools & diagnostics, with first-mover advantage in many product areas.
  • But the larger players have taken notice – with M&A and capacity expansion investments, thus concerning the analyst about future growth prospects in what could become a very crowded market.
  • Price Action: RGEN shares are up 1.47% at $171.61 on the last check Wednesday.
  • Photo Via Company
Market News and Data brought to you by Benzinga APIs
Price Target
Posted In: Analyst ColorNewsHealth CarePrice TargetInitiationAnalyst RatingsMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!